Skip to main content

Table 1 Prevalence of features of metabolic syndrome at baseline in patients assigned to placebo in the FIELD study (points of difference in criteria are shown in bold)

From: Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial

Feature of metabolic syndrome Men Women All patients
  (n = 3067) (n = 1833) (n = 4900)
ATPIII criteria (any 3)    
Diabetes or impaired fasting glucose 100 100 100
High waist measurement (M > 102 cm, F > 88 cm) 54.5 80.6 64.3
Hypertension history or BP ≥ 130/85 mmHg 82.2 85.8 83.6
High triglycerides (≥ 1.7 mmol/L) 50.0 54.1 51.5
Low HDL cholesterol (M < 1.03 mmol/L, F < 1.29 mmol/L) 54.8 66.2 59.1
Metabolic syndrome according to ATPIII 78.3 90.3 82.8
IDF criteria (waist + any 2)    
Diabetes or impaired fasting glucose 100 100 100
High waist measurement (M ≥ 94 cm, F ≥ 80 cm) 83.9 95.0 88.0
Hypertension history or BP ≥ 130/85 mmHg 82.2 85.8 83.6
High triglycerides (≥ 1.7 mmol/L) 50.0 54.1 51.5
Low HDL cholesterol (M < 1.03 mmol/L, F < 1.29 mmol/L) 54.8 66.2 59.1
Metabolic syndrome according to IDF 80.5 92.5 85.0
Harmonized criteria (any 3)    
Diabetes or impaired fasting glucose 100 100 100
High waist measurement (M ≥ 94 cm, F ≥ 80 cm) 83.9 95.0 88.0
Hypertension history or BP ≥ 130/85 mmHg 82.2 85.8 83.6
High triglycerides (≥ 1.7 mmol/L) 50.0 54.1 51.5
Low HDL cholesterol (M < 1.03 mmol/L, F < 1.29 mmol/L) 54.8 66.2 59.1
Metabolic syndrome according to harmonized definition 87.6 94.7 90.3
WHO criteria (diabetes + any 2)    
Diabetes or impaired fasting glucose 100 100 100
High waist-hip ratio (M > 0.9, F > 0.85) or BMI > 30 88.5 80.5 85.5
Hypertension history or blood pressure ≥ 140/90 mmHg 68.5 73.3 70.3
High triglycerides (≥ 1.7 mmol/L) and/or low HDL-c (M < 0.9 mmol/L, F < 1.0 mmol/L) 58.9 59.0 58.9
Microalbuminuria (urine albumin/creatinine ≥ 3.4 mg/mmol) 23.6 20.8 22.6
Metabolic syndrome according to WHO 82.6 80.7 81.9
  1. * IDF criteria for hypertension, high triglyceride, and low HDL-c are the same as those for ATPIII.
  2. † Harmonized criteria are the same as for IDF except metabolic syndrome does not require high waist measurement.
  3. ‡ Ethnic and sex-specific cut-offs for waist circumference define high risk in the harmonized definition. This analysis, for a population mainly of European origin, used the "Caucasian" waist cut-off.
  4. FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; ATPIII, Adult Treatment Panel III; M, male; F, female; BP, blood pressure; IDF, International Diabetes Federation; WHO, World Health Organization; HDL-c, high-density lipoprotein cholesterol